Swedish vaccine provider Svea Vaccin is facing renewed scrutiny following the revelation of further deficiencies, building on previous issues. Reports indicate that vaccines have been stored at incorrect temperatures – specifically, too warm – for a period of 2.5 years. This latest disclosure follows an initial exposé of problems at the facility. The extent of the impact on vaccine efficacy is currently unknown and is under investigation by relevant authorities. These failures raise concerns about the integrity of vaccinations administered using potentially compromised doses. Svea Vaccin has not yet released a comprehensive statement addressing the new findings, but officials have acknowledged the ongoing investigation and pledged cooperation.